Kumar Palanirajan V, Maki Marwan A Abdelkarim, Wei Yeong S, Tatt Lee M, Elumalai Manogaran, Cheah Shiau-Chuen, Raghavan Bharathy, Majeed Abu Bakar Bin A
Department of Pharmaceutical Sciences, UCSI University, Jalan Menara Gading 1, Taman Connaught, Wilayah Persekutuan Kuala Lumpur, 56000, Malaysia.
Department of Medicine & Health Science, UCSI University, Jalan Menara Gading, UCSI Heights, Cheras, Kuala Lumpur, 56000 Selangor, Malaysia.
Curr Clin Pharmacol. 2019;14(2):132-140. doi: 10.2174/1574884714666181120103907.
Recombinant human keratinocyte growth factor (rHuKGF) has gained considerable attention by researchers as epithelial cells proliferating agent. Moreover, intravenous truncated rHuKGF (palifermin) has been approved by Food and Drug Administration (FDA) to treat and prevent chemotherapy-induced oral mucositis and small intestine ulceration. The labile structure and short circulation time of rHuKGF in-vivo are the main obstacles that reduce the oral bioactivity and dosage of such proteins at the target site.
Formulation of methacrylic acid-methyl methacrylate copolymer-coated capsules filled with chitosan nanoparticles loaded with rHuKGF for oral delivery.
We report on chitosan nanoparticles (CNPs) with diameter < 200 nm, prepared by ionic gelation, loaded with rHuKGF and filled in methacrylic acid-methyl methacrylate copolymercoated capsules for oral delivery. The pharmacokinetic parameters were determined based on the serum levels of rHuKGF, following a single intravenous (IV) or oral dosages using a rabbit model. Furthermore, fluorescent microscope imaging was conducted to investigate the cellular uptake of the rhodamine-labelled rHuKGF-loaded nanoparticles. The proliferation effect of the formulation on FHs 74 Int cells was studied as well by MTT assay.
The mucoadhesive and absorption enhancement properties of chitosan and the protective effect of methacrylic acid-methyl methacrylate copolymer against rHuKGF release at the stomach, low pH, were combined to promote and ensure rHuKGF intestinal delivery and increase serum levels of rHuKGF. In addition, in-vitro studies revealed the protein bioactivity since rHuKGFloaded CNPs significantly increased the proliferation of FHs 74 Int cells.
The study revealed that oral administration of rHuKGF-loaded CNPs in methacrylic acid-methyl methacrylate copolymer-coated capsules is practically alternative to the IV administration since the absolute bioavailability of the orally administered rHuKGF-loaded CNPs, using the rabbit as animal model, was 69%. Fluorescent microscope imaging revealed that rhodaminelabelled rHuKGF-loaded CNPs were taken up by FHs 74 Int cells, after 6 hours' incubation time, followed by increase in the proliferation rate.
重组人角质形成细胞生长因子(rHuKGF)作为上皮细胞增殖剂受到了研究人员的广泛关注。此外,静脉注射截短型rHuKGF(帕利夫明)已获美国食品药品监督管理局(FDA)批准,用于治疗和预防化疗引起的口腔黏膜炎及小肠溃疡。rHuKGF在体内结构不稳定且循环时间短,这是降低此类蛋白质在靶部位口服生物活性和剂量的主要障碍。
制备填充有载rHuKGF壳聚糖纳米粒的甲基丙烯酸 - 甲基丙烯酸甲酯共聚物包衣胶囊用于口服给药。
我们报道了通过离子凝胶法制备的直径小于200 nm的壳聚糖纳米粒(CNPs),其负载rHuKGF并填充于甲基丙烯酸 - 甲基丙烯酸甲酯共聚物包衣胶囊中用于口服给药。使用兔模型,根据单次静脉注射(IV)或口服剂量后rHuKGF的血清水平测定药代动力学参数。此外,进行荧光显微镜成像以研究罗丹明标记的载rHuKGF纳米粒的细胞摄取情况。还通过MTT法研究了该制剂对FHs 74 Int细胞的增殖作用。
壳聚糖的黏膜黏附及吸收增强特性与甲基丙烯酸 - 甲基丙烯酸甲酯共聚物在低pH值的胃中对rHuKGF释放的保护作用相结合,可以促进并确保rHuKGF的肠道递送,提高rHuKGF的血清水平。此外,体外研究显示了蛋白质的生物活性,因为载rHuKGF的CNPs显著增加了FHs 74 Int细胞的增殖。
该研究表明,以兔为动物模型,口服载于甲基丙烯酸 - 甲基丙烯酸甲酯共聚物包衣胶囊中的rHuKGF - CNPs实际上可替代静脉注射给药,因为口服载rHuKGF - CNPs的绝对生物利用度为69%。荧光显微镜成像显示,孵育6小时后,罗丹明标记的载rHuKGF - CNPs被FHs 74 Int细胞摄取,随后增殖率增加。